Vascular response to overlapping everolimus-eluting stents. - Comparison with paclitaxel-eluting stents -.
BACKGROUND
Overlapping drug-eluting stents might be associated with an adverse vessel response because of increased drug/polymer toxicity and lesion rigidity.


RESULTS
Lesions treated with overlapping everolimus- (EES=36) or paclitaxel-eluting stents (PES=38) were analyzed for 8-9-months by 3-dimensional intravascular ultrasound. EES were associated with significantly greater neointimal suppression in the single-strut regions than PES, with a similar trend in the overlap region. PES had significant vessel expansion in all regions, whereas there were no changes with EES. Neither stent fracture nor late incomplete stent apposition (LISA) in the overlap region was observed.


CONCLUSIONS
Overlapping EES appears to be effective without vessel expansion, stent fracture or LISA for up to 8-9 months.
Otake
Hiromasa
H
Center for Research in Cardiovascular Interventions, Stanford University, CA 94305-5637, USA.
Honda
Yasuhiro
Y
Yamasaki
Masao
M
Tsujino
Ichizo
I
Shimohama
Takao
T
Sakurai
Ryota
R
Hasegawa
Takao
T
Waseda
Katsuhisa
K
Ako
Junya
J
Fitzgerald
Peter J
PJ
D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D003920:Diabetes Mellitus / Q000000981:diagnostic imaging / Q000628:therapy; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006949:Hyperlipidemias / Q000000981:diagnostic imaging / Q000628:therapy; D006973:Hypertension / Q000000981:diagnostic imaging / Q000628:therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000494:pharmacology*; D012189:Retrospective Studies; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D018084:Ultrasonography, Interventional
D000972:Antineoplastic Agents, Phytogenic; D007166:Immunosuppressive Agents; D000068338:Everolimus; D017239:Paclitaxel; D020123:Sirolimus